Eli Lilly and Company launched Humalog mix 75/25 kwikpen and Humalog Junior kwikpen for diabetic ketoacidosis treatment market
The
growing prevalence of diabetes and diabetic ketoacidosis is fostering the
growth of the diabetic ketoacidosis treatment market. According to the U.S
National Library of Health, the frequency of diabetic ketoacidosis in adults
with type1 diabetes is high, and approximately one-third of the adults have
severe conditions such as diabetes type-1 and diabetic ketoacidosis.
Additionally, healthcare providers are focused on spreading awareness regarding
diabetes type 1 and diabetic ketoacidosis which is again fostering the growth
of the diabetic ketoacidosis treatment market. For instance, in April 2020,
Diabetes UK, a healthcare and research charity association in England, stated
that the National Health Services should be kept open for emergency conditions such
as diabetic ketoacidosis as they may lead to life-threatening situation.
In August 2020, Eli
Lilly and Company (United States) added two non-branded insulin products
Humalog mix 75/25 kwikpen and Humalog Junior kwikpen at a cost-effective range
to make treatment of type-1 diabetes and its complications such as diabetic
ketoacidosis more affordable.
In 2019, Medtronic,
a medical device company in Ireland, merged with Nova Nordisk, a pharmaceutical
company in Denmark. The aim of this partnership is to develop solutions for
diabetes and diabetic ketoacidosis by combining insulin dosage data from future
Novo Nordisk and smart insulin pens by Medtronic’s Continuous Glucose
Monitoring (CGM) devices.
North
America is expected to lead the global diabetic
ketoacidosis treatment market and this is accredited to the increasing
focus of the pharmaceutical industry to focus increase the availability of
supportive treatment for diabetic ketoacidosis. For instance, in June 2020,
Lexicon Pharmaceutical Inc. announced the use of Zynquista (sotagliflozin) to
balance the risk of diabetic ketoacidosis in adults with type-1 diabetes at the
Virtual 80th American Diabetic Association scientific session.
Diabetic
ketoacidosis is often a dangerous complication of diabetes, which occurs when
your body creates unusually high levels of acid known as ketones in the
bloodstream. Early detection of this condition may help to avoid long-term
complications which are far worse than the immediate discomfort of low glucose
levels. The following symptoms may indicate that diabetic ketoacidosis may be
occurring. Diabetic ketoacidosis are formed when fat is broken down in the
liver instead of being converted into energy. There are two main types of this
condition, one is marked by breath odor and the other by unusual nausea or
vomiting. Breath odor that is fruity-scented breath has been identified as one
of the first warning signs of ketoacidosis in the bloodstream.
Comments
Post a Comment